BNT162b2 mRNA COVID-19 백신 접종 후에 첫 발병한 난치 뇌전증지속상태
New-onset Refractory Status Epilepticus after BNT162b2 mRNA COVID-19 Vaccination
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Increasing importance of vaccination during coronavirus disease 2019 (COVID-19) pandemic, several vaccines were developed. Messenger RNA (mRNA) vaccines including BNT162b2 (Pfizer, New York, NY, USA; BioNTech, Mainz, Germany), mRNA-1273 (Moderna, Cambridge, MA, USA) have been disclosed side effects such as thrombocytopenia, myocarditis and headache in general. In addition, adverse effects due to autoimmune responses induced by spike glycoproteins of mRNA vaccines are rarely reported such as the Guillain-Barre syndrome, autoimmune encephalitis and so on. Herein, we report a rare case of encephalitis with new-onset refractory status epilepticus after BNT162b2 mRNA COVID-19 vaccination improved with immune therapy.
Abstract
Increasing importance of vaccination during coronavirus disease 2019 (COVID-19) pandemic, several vaccines were developed. Messenger RNA (mRNA) vaccines including BNT162b2 (Pfizer, New York, NY, USA; BioNTech, Mainz, Germany), mRNA-1273 (Moderna, Cambridge, MA, USA) have been disclosed side effects such as thrombocytopenia, myocarditis and headache in general. In addition, adverse effects due to autoimmune responses induced by spike glycoproteins of mRNA vaccines are rarely reported such as the Guillain-Barre syndrome, autoimmune encephalitis and so on. Herein, we report a rare case of encephalitis with new-onset refractory status epilepticus after BNT162b2 mRNA COVID-19 vaccination improved with immune therapy.
참고문헌 (10)
- Al-Mashdali AF, "Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone : a case report", Ann Med Surg(Lond), 69, pp.102803~ (2021)
- Klein NP, "Surveillance for adverse events after COVID-19 mRNA vaccination", JAMA, 326, pp.1390~1399 (2021)
- Leitinger M, "Diagnostic accuracy of the Salzburg EEG criteria for nonconvulsive status epilepticus : a retrospective study", Lancet Neurol, 15, pp.1054~1062 (2016)
- Fan HT, "COVID-19 vaccine-induced encephalitis and status epilepticus", QJM, 115, pp.91~93 (2022)
- Shyu S, "Clinical manifestation, management, and outcomes in patients with COVID-19 vaccine-induced acute encephalitis : two case reports and a literature review", Vaccines, 10, pp.1230~ (2022)
- Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
- Joosten EA, "Local acute application of BDNF in the lesioned spinal cord anti-inflammatory and anti-oxidant effects", Neuroreport, 15, pp.1163~1166 (2004)
- Wu SY, "BDNF reverses aging-related microglial activation", J Neuroinflammation, 17, pp.210~ (2020)
- Vojdani A, "Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases", Clin Immunol, 217, pp.108480~ (2020)
- Wan EYF, "Association between the risk of seizure and COVID-19 vaccinations : a self-controlled case-series study", Epilepsia, 63, pp.3100~3110 (2022)